Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.

@article{Raheja2018CorrelatingSM,
  title={Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.},
  author={Radhika Kishore Raheja and Keren Regev and Brian C. Healy and Maria A Mazzola and Vanessa Beynon and Felipe von Glehn and Anu Paul and Camilo D{\'i}az-Cruz and Taha Gholipour and Bonnie I. Glanz and Pia Kivisakk and Tanuja Chitnis and Howard L Weiner and James D. Berry and Roopali Gandhi},
  journal={Muscle & nerve},
  year={2018},
  volume={58 2},
  pages={
          261-269
        }
}
INTRODUCTION Amyotrophic lateral sclerosis (ALS) is a debilitating neurologic disorder with poor survival rates and no clear biomarkers for disease diagnosis and prognosis. METHODS We compared serum microRNA (miRNA) expression from patients with ALS with healthy controls and patients with multiple sclerosis and Alzheimer disease. We also correlated miRNA expression in cross-sectional and longitudinal cohorts of ALS patients with clinical parameters. RESULTS We identified 7 miRNAs (miR-192… CONTINUE READING
3
Twitter Mentions

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

MicroRNAs as Biomarkers in Amyotrophic Lateral Sclerosis

VIEW 8 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 47 REFERENCES

Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis : a randomised , double - blind , placebo - controlled trial

D Petrov, C Mansfield, A Moussy, O Hermine
  • Lancet Neurol
  • 2017